Adaptive Biotechnologies Corporation
ADPT
주식 순위
#4121
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
주가
$24.65
시가총액
$3.93B
변동 (1일)
2.92%
변동 (1년)
38.25%
국가
US
거래 Adaptive Biotechnologies Corporation (ADPT)
카테고리
Healthcare
Adaptive Biotechnologies Corporation (ADPT)의 P/E 비율
October 2026 기준 P/E 비율 TTM: -62.89
Adaptive Biotechnologies Corporation의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 -62.89입니다. 2024년 말 기준 P/E 비율은 -5.53였습니다.
Adaptive Biotechnologies Corporation의 P/E 비율 기록 (2017 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | -62.89 | 51.86% |
| 2025 | -41.41 | 648.33% |
| 2024 | -5.53 | 76.19% |
| 2023 | -3.14 | -58.90% |
| 2022 | -7.64 | -60.10% |
| 2021 | -19.15 | -65.53% |
| 2020 | -55.56 | -12.15% |
| 2019 | -63.25 | -30.86% |
| 2018 | -91.48 | -7.79% |
| 2017 | -99.20 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 28.78 | -145.77% |
US
|
|
| -28.36 | -54.91% |
US
|
|
| -24.57 | -60.93% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -148.23% |
NL
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.